Clinical Trials Browser

Phase 3 × Neuroendocrine Tumors × 1 year × Clear all

NCT00569127 2026-03-18

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

Neuroendocrine Tumors

NCT03375320 2026-03-18

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 1 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

Phase 3 Recruiting

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

NCT05477576 2026-01-20

ACTION-1

Phase 3 Recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06881992 2025-12-30

Tumor HI

Phase 3 Recruiting

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT07185672 2025-09-22

PReCedeNT

Phase 3 Recruiting

Neuroendocrine Tumors

NCT04919226 2025-09-10

COMPOSE

Phase 3 Active not recruiting

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT05387603 2025-09-10

START-NET

Phase 3 Recruiting

Neuroendocrine Tumors

NCT05459844 2025-09-05

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Phase 3 Active not recruiting

Neuroendocrine Tumors

NCT06878664 2025-09-02

RIALTO

Phase 3 Recruiting

Neuroendocrine Tumors

NCT03049189 2025-05-30

COMPETE

Phase 3 Active not recruiting

Neuroendocrine Tumors

NCT02246127 2025-05-11

SEQTOR

Phase 3 Completed

141 enrolled 27 charts

Neuroendocrine Tumors